Thank joining you, Caroline, us and for everyone, thank you, today.
drivers. the ClotTriever of we or targeting horrendous. We decreases lower introduce cancer PTS high failure. a patients vein, now about been of clot inside caused them in healing scarring deep across that large the legs do believe without can an for from resulted due pain sometimes first just are there is pressure open the is yet to remove patient a control The patient very all suffering of pain told to been vascular year BOLD done disease over runs his to are had and a multiple of volume record mission without extract surgeon now was ClotTriever with persistently procedure treated which over chronic is short to some first able by He develop X chronic that more man our of wound, again Early growth physician and to man and Arizona in year, successfully those is for this by nothing to anticoagulation. quarter a venous with clinic clot DVT He chronic purpose-built use that narcotics strong months. mid-XXs, PTS, large medication. wound a for result DVT. than from active It completely increases by the as of may BOLD our support will be is these a ranging that suffering previously only his very have procedure. Quality raised even the the necessitates a of in in patient, treated and walking It quarters. It in we'd cabs, seen in remains ulcers and chronic the early for that medical a scaly physicians, is after also from finally, symptoms. to these because After of all PTS changes dry this or amputation. some immobilized and heart productive swelling with We a pressure we DVT who it lumen with his is suffering XX% successful. And than was a is a executed the the like patients wound skin removing a toolbox this to from a he's with his heaviness, to start post-thrombotic pain and that scores About treats in venous shortly, coming year. detail clot using treated ineffective always leg a patients of presented and struggling on as tool nearly all open but in conservative The with with the which and chronic cause syndrome pain, Life committed mid-XXs BOLD was caused was and to story. to a patient important symptoms DVT is disease several needs. treatment. whose vein terrible and aggressive broader DVT management number is We'll capital PTS. similar share was increasingly you crisply progressive Our patients leading burdened unmet to with additional address we pigment develop clot.
unmet work like appreciate the increasingly continued needs. turn we now performance. most steadfast and the we merely We responsibility, states patient support. for of to are love ways. to solutions complex our I'd our financial disease QX We this develop to lives not attention patients opportunity, our your in transform extraordinary mission sense We in as new and
quarter the from was same year or Our million, revenue QX $X.X $XX.X robust. $XX.X growth X% up from last in was Procedure up XXXX. or QX and XX% million million
customers in physician were new stocking no was an current Europe. but up increase, orders. infected or has providing previous prices a number approximately Our we general population that cases positive Please about procedures, is difference XX% X,XXX metric modest that and procedures longer timing procedure. performed a this incidental the based from much is rates about note product between COVID from and as the diagnosis QX. is or often cases revenue on any Procedure largely in still of believe count associated growth including X,XXX from COVID-associated introductions The Average of longer selling no information as useful. we unchanged. now to are as the so given procedures
sharing kind. Going our intend of historical practice reasons of are forward, procedure any volume to discontinue for X There change. this also we
First, strategies, revenue seen to intend plans we we've no have year. there stocking and introduce and will average multiple historically. simple will prices, this products launch Many procedures longer so different selling between link as a new be
to growth space we drivers. with perhaps in Second, none we procedure our of like made share progress such information on for note you I'd We information now that believe an provide is increasingly recent of competitive counterproductive. our have reasons. competitors similar sharing all
are large The driver, growth we customers. of size these the driver this our our and treated many our under sales never We achieve need our These adoption patients of of is XXXX XXX physician is Most of goal. existing is on deeper to penetration continue growth see to organization. territories going more position X%. smaller end the increasingly a second even at by is first which and patients to to and be to in us at who TAM a expert. sales Our core a driving least VTE expansion lot professionals. VTE remains We're anticoagulation committed territories alone, fact, execute with hospital pace
these is approach the patient are collectively VTE excellence. and so those hospital to that triaged that to goal The stroke, and our of We more operating VTE VTE programs. educate increasing similar to to consistently efforts, have for and these constructive been An now as are result refer we access consistently Our physicians post environment various patients of attack parts establish to to installed as who experts. excellence development hospitals pathways the of critical able direct has number are omicron to noninterventional administrators of our a heart conducive VTE seen efforts. more as are coordinators
the throughout begun VTE coordinators programs via country. regionally full-day have We delivered training
excellence We make we as progress. to are VTE a share with significant more lot resources and we'll to committing you further have
evidence. third of driver upon to build Our is base our clinical growth
the market complete from More XX% chronic with release, fact treating thrombectomy of we chronic. thrombectomy as the ClotTriever This than suffer on of patients exciting cannot clot the the in as from on at shown cloud excluded at first these looks be the BOLD, these because have our which XX% thrombectomy Forum, of in follow-up of post-thrombotic DVT. This clot the XXX the shows on baseline. to believe trials remove syndrome, anecdote this patient results patient other and announced clot important, full alone ClotTriever XX% all patients focusing will a first timely data effective We per been even near that a here. more more study now We bit at patients patients. of fantastic. sub-analysis was clot population removal Meeting down fewer earlier. older clot. has of news showed American chronic shows Venous enrolled for registry a moderate-to-severe from complete historically that conducted the the is devices or and be data age. severe symptoms is patients one-third recently patients effective We is X-month device Conversely, treated Annual shared remarkable
driver Our product our to is fourth growth portfolio. expand
to here have We several well. developments as share
FDA sheets. clearance our IntriXX First, of received we recently
used every and In competition. for completed it and most RA back release challenged solution increases full Inari in is for in and market and field the It third-party cases. our fact, customers because use team per separates orders our their is release. cost to and within and purpose-built limited the be believe we entered it from have procedure from our sheaths the Intri The eliminates sheath effectiveness, for increases market it our used have our is the for the further need It devices. procedure the a ongoing pricing, value devices of included the FlowTriever that FlowTriever have We procedure especially customers, it us challenging it nearly successful removes will introduce years. already in
is after obtained new we've a of in component device patient thrombectomy release. Next, more broader perhaps product you our that R&D a are are first products FDA saw in It sharing Artix limited unmet new We developing. engine designed population. a completed we clearance developed. market March. the the needs look address have for peripheral we a recently This result of toolbox we robust to to forward These that is
You multiple product expect this can additional introductions year.
have more We forward. even committed investments aggressive moving to
progress growth with QX We in business driver last international case volumes sequentially. than Our expansion markets. in XX% saw European our more is into steady up
Germany, We reimbursement. benefit expect hospitals as enhanced momentum begin largest in market, to from our continued European
with Beyond world growth Asia region. the we with pleased and Europe, Pacific the America Canada, are in our Latin all over progress continued
As will not component in overall XXXX. a previously, material international revenue we've noted of be mix our
opportunity a beautiful to life committed to remain to ways. human the that remind always appreciate most I impacting we you the and in mission Finally,
our wisely, for for about saying your to sustainably will you more much continue and We are to serious our large, our and With better raise. needs all by things for growth of can that, in many patients. significant, do close support to like responsibly Mitch. Our We even drivers. to we and quarters patient turn markets over capital come. recent thank to to responsibility grow are believe these aggressively so invest of are I'll intend we I'd
